Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07203352
PHASE3

Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL

Sponsor: Nanfang Hospital, Southern Medical University

View on ClinicalTrials.gov

Summary

This prospective, randomized, controlled trial evaluates the efficacy and safety of a new targeted drug combined with chemotherapy versus standard chemotherapy alone. Eligible patients were randomized 1:1 to either the treatment or control group.

Official title: Efficacy and Safety of Targeted Drugs Combined With Chemotherapy in the Treatment of Patients With Newly Diagnosed Acute T-lymphocytic Leukemia

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

154

Start Date

2025-10-01

Completion Date

2026-12-30

Last Updated

2025-10-02

Healthy Volunteers

No

Interventions

DRUG

targeted drug

Patients randomly assigned to the control group will receive standard chemotherapy treatment, but they cannot use targeted drugs in combination.The subjects randomly assigned to the experimental group received targeted drug treatment in addition to the chemotherapy regimen during the second course. Based on the results of bone marrow PCR, subjects with molecular typing of ABL1/ABL2/PDGFRB fusion were to receive chemotherapy combined with dasatinib 100mg orally once a day; subjects with molecular typing of FLT3-ITD positive were to receive chemotherapy combined with sorafenib 400mg orally twice a day.

Locations (1)

Department of Hematology,Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, China